Exabis Library
Welcome to the e-CCO Library!
P653: Ligation of the intersphincteric fistula tract vs. endorectal advancement flap for high perianal fistulas in Crohn’s disease: a retrospective cohort study 
 2019
ECCO '19 Copenhagen
 Friday, 22 February 2019, 9:41 AM
P653: Rheumatic extraintestinal manifestations in ulcerative colitis : Prevalence and predictive factors
 2021
 ECCO'21 Virtual
 Wednesday, 2 June 2021, 4:12 PM
P653: The changing epidemiology of IBD in the western world: a population-based study from Denmark
 2022
 ECCO'22
 Friday, 11 February 2022, 3:56 PM
P653: The efficacy and safety of stem cell therapy for Crohn's disease: a meta-analysis
 2017
 ECCO '17 Barcelona
 Wednesday, 20 February 2019, 10:36 AM
P653: Tight control and Treat to target increase the rates of Transmural remission and Transmural response in Crohn's disease
 2023
 ECCO’23 Copenhagen
 Friday, 14 July 2023, 11:12 AM
P654 Influence of the interval of time between anti-TNF and vedolizumab or ustekinumab in the response to treatment in patients with inflammatory bowel disease 
 2020
ECCO'20 Vienna
 Thursday, 30 January 2020, 10:12 AM
P654: Advances in optimalisation of therapeutic drug monitoring using mucosal TNF expression and anti-TNF concentration in patients with inflammatory bowel disease treated with biologicals: Preliminary results from a single-centre study
 2018
 ECCO '18 Vienna
 Thursday, 21 February 2019, 9:14 AM
P654: Clinical outcomes in familial versus sporadic inflammatory bowel disease diagnosed in the era of biological therapies. Prospective data from the ENEIDA registry.
 2022
 ECCO'22
 Friday, 11 February 2022, 3:56 PM
P654: Controversies in the management of anti-TNF therapy in Crohn's disease patients. A Delphi consensus
 2023
 ECCO’23 Copenhagen
 Friday, 14 July 2023, 11:12 AM
P654: Monitoring of drug concentrations to predict remission under ustekinumab induction therapy in Crohn's disease patients 
 2019
ECCO '19 Copenhagen
 Friday, 22 February 2019, 9:41 AM
P654: Mucosal healing with a second anti-TNF-α in patients with ulcerative colitis after the failure of the previous anti-TNF-α treatment
 2017
 ECCO '17 Barcelona
 Wednesday, 20 February 2019, 10:36 AM
P654: Prevalence of Inflammatory Bowel Disease in young Greek Army male recruits from 2006 to 2018: a thirteen-year retrospective study from a tertiary center
 2021
 ECCO'21 Virtual
 Wednesday, 2 June 2021, 4:12 PM
P655 Pharmacokinetics of ustekinumab in children and adolescents with moderately to severely active Crohn’s disease: Results from UniStar, a phase 1 study 
 2020
ECCO'20 Vienna
 Thursday, 30 January 2020, 10:12 AM
P655: A study to determine factors affecting clinical decision making in outpatients with inflammatory bowel disease
 2017
 ECCO '17 Barcelona
 Wednesday, 20 February 2019, 10:36 AM
P655: Early life mebendazole exposure increases the risk of adult-onset ulcerative colitis: a population-based cohort study
 2022
 ECCO'22
 Friday, 11 February 2022, 3:56 PM
P655: Immunogenicity after transition from adalimumab to ABP 501 in patients with plaque psoriasis
 2018
 ECCO '18 Vienna
 Thursday, 21 February 2019, 9:14 AM
P655: Insulin Resistance Prevalence is Not Increased in Patients with Inflammatory Bowel Disease: a case-control study
 2021
 ECCO'21 Virtual
 Wednesday, 2 June 2021, 4:12 PM
P655: MadCAM1 Negativity of Lamina Propria Endothelial Cells is Associated with Non-Response to Vedolizumab in Inflammatory Bowel Disease Patients
 2023
 ECCO’23 Copenhagen
 Friday, 14 July 2023, 11:12 AM
P655: Microencapsulated Sodium Butyrate significantly modifies the microbiota in patients with inflammatory bowel disease mimicking prebiotic activity and proving effects on the treatment of the disease 
 2019
ECCO '19 Copenhagen
 Friday, 22 February 2019, 9:41 AM
P656 Clinical implications of endoscopic submucosal dissection in management of patients with ulcerative colitis-associated dysplasia 
 2020
ECCO'20 Vienna
 Thursday, 30 January 2020, 10:12 AM